After Raleigh health care diagnostics developer LipoScience agreed to sell to LabCorp at a price per share of less than half its all-time high, it contacted 14 other companies for potential bids, but none would even make an offer.

After Raleigh health care diagnostics developer LipoScience agreed to sell to LabCorp at a price per share of less than half its all-time high, it contacted 14 other companies for potential bids, but none would even make an offer.